Imbalance of T cell subsets in cancer patients and its modification with bestatin, a small molecular immunomodifier.

Experimental immunology Modulatory effects of bestatin on T and B lymphocyte subsets and the concentration of cytokines released by Th1/Th2 lymphocytes in cyclophosphamide-treated mice

“…Kumano et al [18] demonstrated the efficacy of bestatin in restoring the relative proportion of T cell subsets towards a normal balance in cancer patients. In these patients, bestatin administered orally at a daily dose of 30 mg for 6 weeks decreased the percentage and the absolute count of suppressor/cytotoxic T cells (which had been pathologically increased), and raised the value of index CD4+/CD8+ (which had been reduced by the disease).…”

Effects of Bestatin on the Host Immunity in Patients Treated for Urogenital Cancer

“…Several clinical trials with bestatin have been conducted and have suggested improvement of host immune response and prolongation of survival in some cancer types (2)(3)(4)(5). Bestatin has been isolated as a competitive aminopeptidase inhibitor by Umezawa et al ( 6 ) .…”

“…During recent years bestatin has been widely used for cancer immunotherapy (2,3). However, it is not known whether bestatin has a beneficial therapeutic effect nor whether it positively influences the host immunity in these patients.…”

cis-Diamminedichloroplatinum (CDDP)-fosfomycin (FOM) combination in lung cancer patients with respect to the peripheral T lymphocyte subsets.

“…was additionally administered in Group A twice daily for 8 days beginning from day -1. Mononuclear cells were isolated from the heparinized venous blood before and after CDDP administration (on days 7 and 14), and subjected to the indirect immunofluorescence assays for T lymphocytes (T3+) and the major functional subsets (T4+, T8+) as previously described in more detail (Kumano et al 1985). Table 1 summarizes the results.…”